secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2021-11-24T23:59:59+00:00
Accession:  0001493152-21-029741
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients
--------------------------------------------------------------------------------

- Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.
- End-of-treatment mortality: 4.5% OT-101 vs 20% placebo.
- Viral load knockdown >96% in 89% of OT-101 patients vs 67% placebo.
- Overall survival for critical patients: 14 days OT-101 vs 4 days placebo (p<0.0166).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/0001493152-21-029741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-029741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer